Roche Improves Speed and Accuracy of Non-Small Cell Lung Cancer Diagnosis with Launch of Automated Digital Pathology Algorithm

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients.

Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath enterprise software, a universal digital platform for case management, collaboration and reporting. This algorithm will help pathologists to quickly determine whether tumours are positive for the PD-L1 biomarker, highlighting positively and negatively stained tumour cells with a clear visual overlay for easy reference. Patients with tumours that are positive for the PD-L1 biomarker may be eligible for targeted treatment.

"Improving diagnostic consistency and certainty is crucial in providing faster, higher-quality and more accurate diagnoses to cancer patients," said Thomas Schinecker, CEO, Roche Diagnostics. "Our uPath PD-L1 (SP263) image analysis for non-small cell lung cancer is the first next-generation CE-IVD PD-L1 algorithm to the clinical market. It expands on our growing digital pathology suite for VENTANA assays that aid physicians in providing the most accurate treatment decisions for patients with the most common type of lung cancer."

The algorithm's whole-slide automated analysis uses artificial intelligence to provide, with one-click, an actionable assessment of the scanned slide images that is objective and reproducible. The uPath PD-L1 (SP263) image analysis (NSCLC) algorithm for digital pathology is for use on uPath enterprise software.

About uPath image analysis algorithm suite

The uPath image analysis algorithm suite for pathology decision support offers ready-to-use image analysis tools, providing fast, consistent and automated analysis so that pathologists can quickly, accurately and confidently assess immunohistochemistry/in situ hybridization and hematoxylin and eosin-stained slides. This launch of uPath PD-L1 (SP263) image analysis for non-small cell lung cancer follows the January 2019 release of the Roche uPath enterprise software. All algorithms in the suite for uPath software will provide image analysis of VENTANA DP 200 scanned slide images stained with a Roche tissue assay. Together, Roche is delivering a new foundation of its digital pathology solution which will enable the development of artificial intelligence-based image analysis algorithms that can provide pathologists more tools to improve efficiency and precision.

Roche is delivering the end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated clinical image analysis algorithms. Roche minimizes the variables that can impact analysis, and it is this end-to-end development that produces the quality results customers can depend on for making clinical decisions. With the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented tools into routine clinical practice.

About the uPath PD-L1 (SP263) image analysis for NSCLC algorithm

The uPath PD-L1 (SP263) image analysis for NSCLC algorithm is intended for use as an aid to the pathologist in the detection and semi-quantitative measurement of PD-L1 protein in formalin-fixed, paraffin-embedded NSCLC tissue. When used with the CE-marked VENTANA PD-L1 (SP263) Assay, it is indicated for use as an aid in identifying patients for treatment with therapies with the ≥ 50% PD-L1 TC positivity cutoff in accordance with the approved therapeutic product labeling. It is intended for in vitro diagnostic use as an aid to the pathologist in the display, detection, counting, review and classification of tissues and cells of clinical interest based on particular morphology, color, intensity, size, pattern and shape.

About non-small cell lung cancer

Lung cancer is the leading cause of cancer death globally.(1) Each year, 1.76 million people die as a result of the disease, translating into more than 4,800 deaths worldwide every day.(1) Lung cancer can be broadly divided into two major types: NSCLC and small cell lung cancer. NSCLC is the most prevalent type, accounting for about 85% of all cases.(2) NSCLC comprises non-squamous and squamous-cell lung cancer, the squamous form of which is characterised by flat cells covering the airway surface when viewed under a microscope.(2)

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

1. World Health Organization. GLOBOCAN 2018; Lung Cancer: Estimated cancer incidence, mortality and prevalence worldwide. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed November 2019.
2. American Cancer Society. What Is Non-Small Cell Lung Cancer? [Internet]: Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed November 2019.

Most Popular Now

IBM Watson Health Recognizes Top-Perform…

IBM (NYSE: IBM) Watson Health® announced its 2020 Fortune/IBM Watson Health 100 Top Hospitals list and 15 Top Health Systems award winners, naming the top-performing hospitals and health systems in...

Proposed Framework for Integrating Chatb…

While the technology for developing artificial intelligence-powered chatbots has existed for some time, a new viewpoint piece in JAMA lays out the clinical, ethical, and legal aspects that must be...

The New Tattoo: Drawing Electronics on S…

One day, people could monitor their own health conditions by simply picking up a pencil and drawing a bioelectronic device on their skin. In a new study, University of Missouri...

SARS-CoV-2 Antibody Test from Siemens He…

Public Health England, in partnership with the University of Oxford, recently conducted a head-to-head evaluation of four commercial immunoassay tests available in the UK and used for the detection of...

World's Smallest Imaging Device has Hear…

A team of researchers led by the University of Adelaide and University of Stuttgart has used 3D micro-printing to develop the world's smallest, flexible scope for looking inside blood vessels...

Online Tools can Improve Autism Diagnosi…

Online tools and assessments can help speed up diagnosis of autism spectrum disorder (ASD), the first comprehensive survey of research in the field has concluded. The survey showed that using internet-based...

Optimizing Neural Networks on a Brain-In…

Many computational properties are maximized when the dynamics of a network are at a "critical point", a state where systems can quickly change their overall characteristics in fundamental ways, transitioning...

Clinical-Grade Wearables Offer Continuou…

Although it might be tempting to rely on your fitness tracker to catch early signs of COVID-19, Northwestern University researchers caution that consumer wearables are not sophisticated enough to monitor...

New Machine Learning Method Allows Hospi…

To answer medical questions that can be applied to a wide patient population, machine learning models rely on large, diverse datasets from a variety of institutions. However, health systems and...

NHS Lanarkshire to Advance Scotland's Pa…

An early warning system that helps busy doctors, nurses and other healthcare professionals to quickly identify when patients are at risk of deterioration is to be deployed across hospitals and...

Social Media and Radiology - The Good, t…

Bradley Spieler, MD, Vice Chairman of Radiology Research at LSU Health New Orleans School of Medicine, is the lead author of a Radiology Research Alliance paper examining the usefulness of...